Abstract: The present invention relates to novel compounds for modulating the activity of exchange proteins directly activated by cAMP (Epacs). In particular, the present invention relates to cAMP analogues that specifically modulate the activity of Epacs. The invention further relates to pharmaceutical compositions comprising the novel compounds, and the use of the compounds in the treatment of humans and/or animals.
Type:
Application
Filed:
June 10, 2003
Publication date:
May 11, 2006
Applicant:
KYLIX B.V.
Inventors:
John De Koning, Anne Christensen, Frank Schwede, Hans Genieser, Stein Doskeland, Johannes Bos
Abstract: The invention relates to the use of the expression products of the TCF target genes as markers for the isolation of intestinal stem cells in a method for the isolation of intestinal stem cells by providing antibodies, antibody derivatives or ligand fusion proteins against one or more of the target gene products of the genes; providing single cell suspensions of intestinal tissue; contacting the antibodies, antibody derivatives or ligand fusion proteins and the single cell suspensions; identifying the cells binding to the antibodies, antibody derivatives or ligand fusion proteins; and optionally isolating the stem cells from the antibodies, antibody derivatives or ligand fusion proteins.
Type:
Application
Filed:
September 17, 2002
Publication date:
March 25, 2004
Applicant:
Kylix B.V.
Inventors:
Johannes Carolus Clevers, Eduard Batlle Gomez, Marcus Lambertus Van De Wetering, Elena Sancho Suils
Abstract: The invention relates to the use of inhibitors of the expressed proteins of the murine genes and/or their human homologues listed in Table 1 for the preparation of a therapeutical composition for the treatment of cancer, in particular for the treatment of solid tumors of lung, colon, breast, prostate, ovarian, pancreas and leukemia. The invention also relates to the therapeutical compositions comprising the inhibitors and to methods for development of the inhibitor compounds.
Type:
Application
Filed:
August 19, 2002
Publication date:
February 19, 2004
Applicant:
Kylix B.V.
Inventors:
Anders Henrik Lund, Antonius Jozef Maria Berns, Maarten Matthijs Sharif Van Lohuizen, Carla Pedro Martins, Henricus Martinus Maria Mikkers, Jack Richard Lenz
Abstract: The present invention relates to the use of inhibitors of the expressed proteins of TCF target genes whose expression is regulated by TCF/&bgr;-catenin complexes for the preparation of a therapeutical composition for the treatment of cancers in which TCF/&bgr;-catenin signaling is deregulated. Such inhibitors can be antibodies, small molecules, antisense RNA and dsRNA for use in RNAi. The invention also relates to these inhibitors per se.
Type:
Application
Filed:
July 16, 2002
Publication date:
January 8, 2004
Applicant:
Kylix B.V.
Inventors:
Johannes Carolus Clevers, Eduard Batle Gomez, Marcus Lambertus Van De Wetering, Elena Sancho Suils
Abstract: The present invention provides a method of inhibiting or moderating the kinase activity of tyrosine kinases comprising the administration of a compound represented by formula (1) said kinase in sufficient concentration to inhibit or moderate the enzyme activity of said kinase.
Type:
Application
Filed:
January 25, 2002
Publication date:
August 21, 2003
Applicant:
KYLIX, B.V.
Inventors:
Frank Stieber, Klaus Hellmuth, Herbert Waldmann, Ralph Mazitschek, Athanassios Giannis